Literature DB >> 1036928

[Isolation and characterisation of two main metabolites of ifosfamide from human urine (author's transl)].

K Norpoth, G Müller, H Raidt.   

Abstract

Two main metabolites of the cytostatic agent 1,3,2-oxazaphosphorine-3(2-chloroethyl)-2-[(2-chloroethyl)-amino]-tetrahydro-2-oxide (ifosfamidd as two different dechloroethylated derivatives. They both can also be derived from ifosfamide in vitro by means of KMnO4-oxidation. The metabolites are stable in organic solutions and they show no cytotoxic activity in biological test systems. In the urine of a patient treated with ifosfamide, nearly 50% of the applied dose were excreted as dechloroethylated derivatives. In the urine of other patients "carboxyifosfamide" was the main metabolite. It is assumed that the therapeutic effect of ifosfamide depends partially on whether side chain oxidation or ring oxidation is the predominant way of biotransformation.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1036928

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

Review 1.  Ifosfamide/mesna. A review of its antineoplastic activity, pharmacokinetic properties and therapeutic efficacy in cancer.

Authors:  K L Dechant; R N Brogden; T Pilkington; D Faulds
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  Comparative study on human pharmacokinetics of activated ifosfamide and cyclophosphamide by a modified fluorometric test.

Authors:  T Wagner; D Heydrich; T Jork; G Voelcker; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1981       Impact factor: 4.553

Review 3.  Comparative activity of ifosfamide and cyclophosphamide.

Authors:  W Brade; S Seeber; K Herdrich
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

4.  Toxicity of ifosfamide, cyclophosphamide and their metabolites in renal tubular cells in culture.

Authors:  M Mohrmann; S Ansorge; U Schmich; B Schönfeld; M Brandis
Journal:  Pediatr Nephrol       Date:  1994-04       Impact factor: 3.714

Review 5.  Ifosfamide clinical pharmacokinetics.

Authors:  T Wagner
Journal:  Clin Pharmacokinet       Date:  1994-06       Impact factor: 6.447

6.  [Fluorometric determination of "activated" cyclophosphamide and ifosfamide in blood (author's transl)].

Authors:  G Voelcker; R Haeglsperger; H J Hohorst
Journal:  J Cancer Res Clin Oncol       Date:  1979-04-12       Impact factor: 4.553

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.